

Glenmark Pharmaceuticals Limited  
Statement of unaudited financial results for the quarter and half year ended 30 September, 2019 (Rs. In Millions)

	Particulars [ Refer notes below ]	Standalone (Ind AS)					
		Quarter ended 30/09/2019 (Unaudited)	Quarter ended 30/06/2019 (Unaudited)	Quarter ended 30/09/2018 (Unaudited)	Half year ended 30/09/2019 (Unaudited)	Half year ended 30/09/2018 (Unaudited)	Year ended 31/03/2019 (Audited)
I	Revenue from operations						
	(a) Net sales	17,426.23	14,552.33	16,398.12	31,978.56	30,004.80	61,311.40
	(b) Other operating income	471.96	435.60	399.03	907.56	850.72	1,737.27
	Total revenue from operations	17,898.19	14,987.93	16,797.15	32,886.12	30,855.52	63,048.67
II	Other income	1,924.68	685.41	2,263.02	2,610.09	3,918.66	4,756.14
III	Total income ( I + II )	19,822.87	15,673.34	19,060.17	35,496.21	34,774.18	67,804.81
IV	Expenses						
	(a) Cost of materials consumed	5,675.87	5,193.73	3,859.17	10,869.60	7,944.15	15,858.51
	(b) Purchase of stock-in-trade	928.73	966.13	881.14	1,894.86	1,627.86	3,012.95
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	196.85	(92.84)	1,134.01	104.01	1,574.09	4,718.11
	(d) Employee benefits expense	3,457.94	2,200.16	3,123.98	5,658.10	5,136.68	9,699.80
	(e) Finance costs	651.67	680.76	608.53	1,332.43	1,160.24	2,238.14
	(f) Depreciation, amortisation and impairment expense	333.22	321.65	269.23	654.87	542.28	1,062.79
	(g) Other expenses	3,833.52	3,634.31	3,880.74	7,467.83	7,478.99	16,484.52
	Total expenses ( IV )	15,077.80	12,903.90	13,756.80	27,981.70	25,464.29	53,074.82
V	Profit/(loss) before exceptional items and tax ( III - IV )	4,745.07	2,769.44	5,303.37	7,514.51	9,309.89	14,729.99
VI	Exceptional items (Refer note 5)	-	-	(3,451.85)	-	(3,451.85)	(3,451.85)
VII	Profit/(loss) before tax ( V - VI )	4,745.07	2,769.44	8,755.22	7,514.51	12,761.74	18,181.84
VIII	Tax expense :						
	Current tax	713.19	604.77	1,915.64	1,317.96	2,677.19	3,834.95
	Deferred tax	(288.04)	(113.76)	(186.17)	(401.80)	(291.37)	(536.14)
IX	Profit/(loss) for the period from continuing operations ( VII - VIII )	4,319.92	2,278.43	7,025.75	6,598.35	10,375.92	14,883.03
X	Profit/(loss) before tax from discontinuing operations	-	-	683.02	-	1,630.09	2,028.34
XI	Tax expense of discontinuing operations :						
	Current tax	-	-	222.51	-	531.04	650.29
	Deferred tax	-	-	10.67	-	25.47	39.96
XII	Profit/(loss) for the period from discontinuing operations ( X - XI )	-	-	449.84	-	1,073.58	1,338.09
XIII	Profit/(loss) for the period for continuing and discontinuing operations ( IX + XII )	4,319.92	2,278.43	7,475.59	6,598.35	11,449.50	16,221.12
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss	(43.72)	18.03	(48.45)	(25.69)	(23.35)	(54.38)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	14.04	(5.57)	16.93	8.47	8.16	19.00
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total comprehensive income	4,290.24	2,290.89	7,444.07	6,581.13	11,434.31	16,185.74
XVI	Total comprehensive income attributable to:						
	- Non-controlling interests	-	-	-	-	-	-
	- Owners of the Company	4,290.24	2,290.89	7,444.07	6,581.13	11,434.31	16,185.74
XVII	Other equity	-	-	-	-	-	119,138.72
XVIII	Earning per share (EPS) (for continuing operations)						
	(of Re 1/- each) (not annualised)*						
	Basic EPS (in Rupees)	15.31	8.07	24.90	23.38	36.78	52.75
	Diluted EPS (in Rupees)	15.31	8.07	24.90	23.38	36.78	52.74
XIX	Earning per share (EPS) (for discontinuing operations)						
	(of Re 1/- each) (not annualised)*						
	Basic EPS (in Rupees)	-	-	1.59	-	3.80	4.74
	Diluted EPS (in Rupees)	-	-	1.59	-	3.80	4.74
XX	Earning per share (EPS) (for continuing and discontinuing operations)						
	(of Re 1/- each) (not annualised)*						
	Basic EPS (in Rupees)	15.31	8.07	26.49	23.38	40.58	57.49
	Diluted EPS (in Rupees)	15.31	8.07	26.49	23.38	40.58	57.49

Approved on behalf of the Board for the year ended 31 March 2019



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com